Risk of upper gastrointestinal events with the use of various NSAIDs: A case-control study in a general population

References

• Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 43: 1520–8
   Web of Science ®Google Scholar
• Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004; 364: 65–674
   PubMed Web of Science ®Google Scholar
• Silverstein F, Faich G, Goldstein J, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. JAMA 2000; 284: 1247–1255
   PubMed Web of Science ®Google Scholar
• Juni P, Rutjes AW, Dieppe PA. Are selective COX 2 inhibitors superior to traditional non-steroidal anti-inflammatory drugs?. Br Med J 2002; 324: 1287–8
   PubMed Web of Science ®Google Scholar
• Hawkey C, Kahan A, Steinbruck K, et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. Br J Rheumatol 1998; 37: 937–45
   PubMedGoogle Scholar
• Dequeker J, Hawkey C, Kahan A, et al. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis. Br J Rheumatol 1998; 37: 946–51
   PubMedGoogle Scholar
• Henry D, Lim L-Y, Garcia Rodrigues L, et al. Variability in risk of gastrintestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. Br Med J 1996; 312: 1563–6
   PubMed Web of Science ®Google Scholar
• Mamdani M, Rochon P, Juurlink D, et al. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygense-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. Br Med J 2002; 325: 624–7
   PubMed Web of Science ®Google Scholar
• Laporte JR, Ibanez L, Vidal X, et al. Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Safety 2004; 27: 411–20
   PubMed Web of Science ®Google Scholar
• Norgard B, Pedersen L, Johnsen SP, et al. COX-2-selective inhibitors and the risk of upper gastrointestinal bleeding in high-risk patients with previous gastrointestinal diseases: a population-based case-control study. Aliment Pharmacol Ther 2004; 19: 817–25
   PubMed Web of Science ®Google Scholar
• Hippisley-Cox J, Coupland C, Logan R. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. Br Med J 2005; 331: 1310–6
   PubMed Web of Science ®Google Scholar
• Drug consumption statistics. National Agency for Medicines. Available at: http://www.nam.fi/english/medicines/drug_consumption/index.html ( accessed 10.05. 2006).
   Google Scholar
• Helin-Salmivaara A, Klaukka T, Huupponen R, et al. Heavy users of non-steroidal anti-inflammatory drugs: a nationwide prescription database study in Finland. Eur J Clin Pharmacol 2003; 59: 477–82
   PubMed Web of Science ®Google Scholar
• Finnish statistics on medicines (2005) 2004. Helsinki: the National Agency for Medicines and the Social Insurance Institution; .
   Google Scholar
• ATC/DDD system. WHO. Available at: http://www.whocc.no/atcddd/ ( accessed 30.08. 2005).
   Google Scholar
• Hosmer DW, Lemeshow S, Jr. Applied logistic regression. Hoboken, N.J: Wiley & Sons; 2000.
   Google Scholar
• FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001; 345: 433–42
   PubMed Web of Science ®Google Scholar
• Brune K, Hinz B. Selective cyclooxygenase-2 inhibitors: similarities and differences. Scand J Rheumatol 2004; 33: 1–6
   PubMed Web of Science ®Google Scholar
• Barden J, Edwards JE, McQuay HJ, Moore RA. Single dose oral celecoxib for postoperative pain. Cochrane Database Syst Rev 2003; CD004233.
   Google Scholar
• Collins SL, Moore RA, McQuay HJ, Wiffen PJ, Edwards JE. Single dose oral ibuprofen and diclofenac for postoperative pain. Cochrane Database Syst Rev 2000; CD001548.
   Google Scholar
• Barden J, Edwards J, Moore RA, McQuay HJ. Single dose oral diclofenac for postoperative pain. Cochrane Database Syst Rev 2004; CD004768.
   Web of Science ®Google Scholar
• Gabriel S, Jaakkimainen L, Bombardier C. Risk of serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991; 115: 787–96
   PubMed Web of Science ®Google Scholar
• Bollini P, Garcia Rogdiguez L, Gutthann S, et al. The impact of research quality and study design on epidemiologic estimates of the effect of nonsteroidal anti-inflammatory drugs on upper gastrointestinal tract disease. Arch Intern Med 1992; 152: 1289–95
   PubMedGoogle Scholar
• Hernandez-Diaz S, Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000; 160: 2093–9
   PubMed Web of Science ®Google Scholar
• Ofman JJ, Badamgarav E, Henning JM, et al. Utilization of nonsteroidal anti-inflammatory drugs and antisecretory agents: a managed care claims analysis. Am J Med 2004; 116: 835–42
   PubMed Web of Science ®Google Scholar
• Fries JF, Murtagh KN, Bennett M, et al. The rise and decline of nonsteroidal anti-inflammatory drug-associated gastropathy in rheumatoid arthritis. Arthritis Rheum 2004; 50: 2433–40
   PubMed Web of Science ®Google Scholar
• Hooper L, Brown TJ, Elliott R, et al. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. Br Med J 2004; 329: 948
   PubMed Web of Science ®Google Scholar
• Rostom A, Dube C, Wells G, Tugwell P, Welch V, Jolicoeur E, , et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2002, CD002296.
   Google Scholar
• Garner SE, Fidan DD, Frankish RR, Judd MG, Towheed TE, Tugwell P, , et al. Rofecoxib for rheumatoid arthritis. Cochrane Database Syst Rev 2005; CD003685.
   Google Scholar
• Garner SE, Fidan DD, Frankish RR, Maxwell LJ. Rofecoxib for osteoarthritis. Cochrane Database Syst Rev 2005; CD005115.
   Google Scholar
• Moore RA, Derry S, Makinson GT, McQuay HJ. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthritis Res Ther 2005; 7: R644–65
   PubMed Web of Science ®Google Scholar
• Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, et al. MEDAL Steering Committee. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006; 368: 1771–81
   PubMed Web of Science ®Google Scholar
• Zimmermann KC, Sarbia M, Schror K, Weber AA. Constitutive cyclooxygenase-2 expression in healthy human and rabbit gastric mucosa. Mol Pharmacol 1998; 54: 536–40
   PubMed Web of Science ®Google Scholar
• McCarthy CJ, Crofford LJ, Greenson J, Scheiman JM. Cyclooxygenase-2 expression in gastric antral mucosa before and after eradication of Helicobacter pylori infection. Am J Gastroenterol 1999; 94: 1218–23
   PubMed Web of Science ®Google Scholar
• Mizuno H, Sakamoto C, Matsuda K, Wada K, Uchida T, Noguchi H, et al. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 1997; 112: 387–97
   PubMed Web of Science ®Google Scholar
• Weil J, Colin-Jones D, Langman M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. Br Med J 1995; 310: 827–30
   PubMed Web of Science ®Google Scholar
• MacDonald TM, Morant SV, Goldstein JL, et al. Channeling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs and older, non-specific non-steroidal anti-inflammatory drugs. Gut 2003; 52: 1265–70
   PubMed Web of Science ®Google Scholar
• Huupponen R, Helin-Salmivaara A, Sairanen S, et al. Painkillers are used differently in Finland compared to other Nordic countries (in Finnish). Finn Med J 2001; 56: 1904–8
   Google Scholar
• Helin-Salmivaara A, Virtanen A, Vesalainen R, et al. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Eur Heart J 2006; 27: 1657–63
   PubMed Web of Science ®Google Scholar